Search research articles
Contact Us
Filters
Showing results (291-300 of 331) with videos related to
Page
of 34
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 25, 2019
Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415
Maria Thor, Joseph O Deasy, Rebecca Paulus, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)
Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 2, 2023
Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer
Himanshu R Lukka, Snehal Deshmukh, Deborah W Bruner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2016
Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy
Rahul D Tendulkar, Shree Agrawal, Tianming Gao, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 2, 2024
Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate Cancer
Amy J Wisdom, Beow Y Yeap, Jeff M Michalski, et al.
JAMA Oncology
|
March 14, 2024
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial
Mark K Buyyounouski, Stephanie L Pugh, Ronald C Chen, et al.
Clinical and Translational Radiation Oncology
|
January 19, 2019
A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database
Benjamin W Fischer-Valuck, Jeff M Michalski, Jessika A Contreras, et al.
JCO Clinical Cancer Informatics
|
July 1, 2022
Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415
Rahul Khairnar, Lyudmila DeMora, Howard M Sandler, et al.
Cancer
|
December 29, 2022
Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126
Andrew M McDonald, Lyudmila DeMora, Eddy S Yang, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 8, 2022
The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521
William A Hall, Theodore G Karrison, Seth A Rosenthal, et al.
Page
of 34
Search research articles
Search
Showing results (291-300 of 331) with videos related to
Sort By:
Page
of 34
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 25, 2019
Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415
Maria Thor, Joseph O Deasy, Rebecca Paulus, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)
Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 2, 2023
Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer
Himanshu R Lukka, Snehal Deshmukh, Deborah W Bruner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2016
Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy
Rahul D Tendulkar, Shree Agrawal, Tianming Gao, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 2, 2024
Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate Cancer
Amy J Wisdom, Beow Y Yeap, Jeff M Michalski, et al.
JAMA Oncology
|
March 14, 2024
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial
Mark K Buyyounouski, Stephanie L Pugh, Ronald C Chen, et al.
Clinical and Translational Radiation Oncology
|
January 19, 2019
A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database
Benjamin W Fischer-Valuck, Jeff M Michalski, Jessika A Contreras, et al.
JCO Clinical Cancer Informatics
|
July 1, 2022
Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415
Rahul Khairnar, Lyudmila DeMora, Howard M Sandler, et al.
Cancer
|
December 29, 2022
Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126
Andrew M McDonald, Lyudmila DeMora, Eddy S Yang, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 8, 2022
The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521
William A Hall, Theodore G Karrison, Seth A Rosenthal, et al.
Page
of 34